NL-OMON38068已完成2 期
ADMINISTRATION OF HA-1 TCR TRANSDUCED VIRUS-SPECIFIC T-CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK LEUKEMIA (LUMC 2010-02) - HA-1 TCR transduced virus-specific T-cells
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age 18-75 years
- •WHO performance score 0-2
- •High-risk leukemia (see appendix D)
- •Complete remission (CR) or stable partial remission (PR) (see appendix D)
- •HLA-A*0201 positive
- •HA-1h positive
- •Availability of a suitable donor (see donor criteria)
- •Written informed consent
排除标准
- •Life expectation < 3 months.
- •End stage irreversible multi-system organ failure.
- •Pregnant or lactating women.
- •Severe psychological disturbances.
- •HIV-positivity
研究者
相似试验
进行中（未招募）
1 期
ADMINISTRATION OF HA-1 TCR TRANSDUCED VIRUS-SPECIFIC T-CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK LEUKEMIAhigh risk leukemiaEUCTR2010-024625-20-NLeiden University Medical Center20
尚未招募
不适用
ADMINISTRATION OF HA-1 TCR TRANSDUCED VIRUS-SPECIFIC T-CELLSAFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITHHIGH-RISK LEUKEMIA.high risk leukemiaNL-OMON26148eiden University Medical Center (LUMC)20
进行中（未招募）
1 期
Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanomaEUCTR2008-006253-41-NOThe Norwegian Radium Hospital, Oslo University Hospital25
招募中
2 期
Oncolytic virus therapy using G47delta for patients with prostate cancerprostae cancerprostate cancer, oncolytic, genetically engineered virus, virus therapy, gene therapy, cancer treatment, herpes simplex virus type1JPRN-jRCTs033210603Hiroshi Fukuahra30
尚未招募
不适用
TCR repertoire analysis after Hepatitis A vaccinatioAgeingImmune response with ageTCR repertoire10027665NL-OMON56630niversitair Medisch Centrum Utrecht145